Developer docs
API playgroundTry for free, no card

Search company profiles

Avenacy

Full company profile

uuid0000h1w

Namestring
Avenacy
Legal namestring
Avenacy, Inc.
Websiteurl
avenacy.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Avenacy is a U.S. specialty pharmaceutical company founded in October 2023 and headquartered in Schaumburg, Illinois, focused on commercializing FDA-approved generic sterile injectable medications for acute care hospitals, outpatient clinics, physician offices, and — more recently — mail order and retail pharmacy channels. The company operates an asset-light model, sourcing its 28 launched products (as of June 2026) from a global network of nearly 20 cGMP-certified development and manufacturing partners across five key geographies. Its portfolio spans oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular and anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), a foundational antibiotic portfolio (Ampicillin, Penicillin G, Piperacillin-Tazobactam, Nafcillin, Doxycycline, Ampicillin-Sulbactam), anesthetics (Propofol, Lidocaine), and other critical care injectables (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine, Diphenhydramine, Bortezomib).

Avenacy differentiates through proprietary highly-visible label designs intended to reduce administration errors and improper doses, as well as ready-to-use formulations such as Magnesium Sulfate premix IV bags and Tranexamic Acid in 0.7% Sodium Chloride. Products are distributed primarily through U.S. wholesale distribution partners, with the company building a regional field sales team of Regional Business Development Managers to develop direct relationships with hospital and alternate care purchasers. Management is led by CEO and co-founder Jeff Yordon (formerly of Sagent Pharmaceuticals and Athenex Pharmaceutical Division), co-founder Kam Phulwani, and co-founder and board member Dr. Patrick Soon-Shiong (NantCapital).

The company generates revenue through unit sales of generic injectable pharmaceuticals at undisclosed pricing, with individual product U.S. market sizes ranging from approximately $8 million to $71 million annually. Avenacy has reported FY2025 year-over-year revenue growth of 212% and gross profit expansion of 335%, with over 3 million units sold since January 2024 and a 25-product milestone achieved by year-end 2025. It has raised capital through a NantCapital investment (August 2024), an approximately $26 million equity round (November 2024), and an Asset Based Lending facility with Texas Capital Bank (June 2025), supporting plans to launch 14 or more additional products in 2026 and continued channel expansion.

Short descriptiontext

Avenacy is a U.S. specialty pharmaceutical company founded in 2023 that commercializes FDA-approved generic sterile injectable medications across oncology, antibiotics, cardiovascular, and critical care through a network of cGMP manufacturing partners, selling to hospitals, clinics, and pharmacies via wholesale distribution and a growing field sales team.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchaumburg, United States
HQ citystring
Schaumburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic injectable pharmaceuticals, sterile injectable medications, specialty pharmaceutical manufacturing, critical care injectables, generic drug distribution
Industry1 code
PRIMARYHLAIABAC
Sterile Injectable Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Injectable Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Injectable Pharmaceuticals Sales
TypeOne Time License
Description

Avenacy generates revenue through the sale of FDA-approved generic injectable medications to healthcare facilities including hospitals, outpatient clinics, and physician offices. Products are distributed through wholesale partners. Each product launch represents a potential revenue stream from unit sales, with market sizes for individual products ranging from approximately $8 million to $71 million annually in the U.S.

avenacy.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avenacy is a specialty pharmaceutical company that develops, manufactures, and distributes FDA-approved generic injectable medications for U.S. healthcare facilities. Its portfolio of 28 launched sterile injectable products spans oncology, antibiotics, antiemetics, cardiovascular, and anesthesia therapeutic areas. Avenacy differentiates through proprietary highly visible packaging/labeling and ready-to-use formulations designed to reduce administration errors, leveraging a global network of nearly 20 cGMP-certified development and manufacturing partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 3 million units sold since January 2024
+2 more records
Product overview1 text field

Avenacy is a specialty pharmaceutical company offering a portfolio of sterile injectable generic medications for U.S. healthcare facilities. The product portfolio consists of FDA-approved generic equivalents of branded injectable drugs spanning multiple therapeutic areas including oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular/anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), antibiotics (Ampicillin, Penicillin G, Piperacillin/Tazobactam, Nafcillin, Doxycycline), anesthetics (Lidocaine, Propofol), and other critical care medications (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine). The portfolio includes both standard vials and ready-to-use formulations. The company differentiates through unique packaging and labeling designed to reduce medication errors. The products are distributed to acute care hospitals, outpatient clinics, and physician offices through wholesale partners.

Product and service26 records
1Melphalan for Injection
CategorySterile Injectable / Oncology
Description

Generic equivalent of Alkeran; 50 mg lyophilized powder kit for palliative treatment of multiple myeloma, supplied to hospitals and oncology treatment centers.

2Bivalirudin for Injection
CategorySterile Injectable / Cardiovascular Anticoagulation
Description

Generic equivalent of Angiomax; 250 mg lyophilized powder single-dose vial anticoagulant used during percutaneous coronary intervention (PCI) and for heparin-induced thrombocytopenia.

3Fosaprepitant for Injection
CategorySterile Injectable / Antiemetic
Description

Generic equivalent of Emend; 150 mg single-dose vial antiemetic for chemotherapy-induced nausea and vomiting in oncology settings.

4Fulvestrant Injection
CategorySterile Injectable / Oncology
Description

Generic equivalent of Faslodex; 250 mg per 5 mL prefilled syringe for HR-positive, HER2-negative advanced breast cancer.

5Furosemide for Injection, USP
CategorySterile Injectable / Diuretic
Description

Generic equivalent of Lasix; 100 mg per 10 mL loop diuretic for edema associated with congestive heart failure, cirrhosis, and renal disease.

6Desmopressin Acetate for Injection, USP
CategorySterile Injectable / Endocrine
Description

Generic equivalent of DDAVP; 4 mcg/mL single-dose and 40 mcg/10 mL multi-dose vials for central diabetes insipidus, hemophilia A, and von Willebrand's disease.

7Eptifibatide Injection
CategorySterile Injectable / Cardiovascular Antiplatelet
Description

Generic equivalent of Integrilin; 75 mg per 100 mL antiplatelet for acute coronary syndrome and PCI procedures.

8Magnesium Sulfate in Water for Injection
CategorySterile Injectable / Critical Care
Description

Ready-to-Use Premix IV bags of magnesium sulfate in 2g/50mL, 4g/100mL, and 4g/50mL concentrations for seizure prevention in preeclampsia/eclampsia and other obstetric and critical care uses.

9Isoproterenol Hydrochloride Injection, USP
CategorySterile Injectable / Cardiovascular
Description

Generic equivalent of ISUPREL; 0.2 mg/mL and 1 mg/5 mL presentations for heart block, cardiac arrest, bronchospasm during anesthesia, and shock states.

10Tranexamic Acid Injection, USP
CategorySterile Injectable / Hematology
Description

Generic equivalent of Cyklokapron; 1000 mg per 10 mL antifibrinolytic for reducing hemorrhage in hemophilia patients during tooth extraction and related bleeding indications.

11Prochlorperazine Edisylate Injection, USP
CategorySterile Injectable / Antiemetic / Antipsychotic
Description

Generic equivalent of COMPAZINE; 10 mg per 2 mL multi-dose vial phenothiazine for controlling severe nausea/vomiting and schizophrenia.

12Palonosetron Hydrochloride Injection, USP
CategorySterile Injectable / Antiemetic
Description

Generic equivalent of Aloxi; 5-HT3 antagonist antiemetic for chemotherapy-induced and postoperative nausea and vomiting.

13Metoclopramide Injection, USP
CategorySterile Injectable / Antiemetic / GI
Description

Generic equivalent of Reglan; 10 mg per 2 mL for diabetic gastroparesis, chemotherapy-induced nausea, postoperative nausea, small bowel intubation, and radiological examination.

14Dexmedetomidine Injection, USP
CategorySterile Injectable / ICU Sedation
Description

Generic equivalent of Precedex; 200 mcg per 2 mL single-dose vial sedative for ICU and procedural sedation.

15Zoledronic Acid Injection
CategorySterile Injectable / Oncology Support
Description

Generic equivalent of Zometa; 4 mg per 5 mL single-dose vial bisphosphonate for bone metastases and hypercalcemia of malignancy.

16Ampicillin for Injection, USP
CategorySterile Injectable / Antibiotic
Description

Ampicillin broad-spectrum penicillin antibiotic in 10 g pharmacy bulk package for treating susceptible bacterial infections in hospital settings.

17Ampicillin and Sulbactam for Injection, USP
CategorySterile Injectable / Antibiotic
Description

Ampicillin-sulbactam combination antibiotic in 1.5 g, 3 g single-dose vials and 15 g pharmacy bulk package for treating bacterial infections.

18Nafcillin for Injection, USP
CategorySterile Injectable / Antibiotic
Description

Nafcillin penicillinase-resistant penicillin antibiotic in 10 g pharmacy bulk package for treating staphylococcal infections.

19Penicillin G Potassium for Injection, USP
CategorySterile Injectable / Antibiotic
Description

Penicillin G Potassium antibiotic in 5,000,000 and 20,000,000 unit glass vials for treating susceptible bacterial infections.

20Piperacillin and Tazobactam for Injection, USP
CategorySterile Injectable / Antibiotic
Description

Piperacillin-tazobactam combination antibiotic in 3.375 g, 4.5 g single-dose vials and 40.5 g pharmacy bulk package for treating bacterial infections.

21Propofol Injectable Emulsion, USP
CategorySterile Injectable / Anesthesia
Description

Generic equivalent of Diprivan; 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL single-dose vials for sedation and anesthesia.

22Lidocaine HCl Injection, USP
CategorySterile Injectable / Anesthesia
Description

Generic equivalent of XYLOCAINE; 1% lidocaine in 20 mg/2 mL, 50 mg/5 mL, 300 mg/30 mL, and 500 mg/50 mL presentations for local or regional anesthesia.

23Leuprolide Acetate Injection
CategorySterile Injectable / Hormonal Therapy
Description

14 mg per 2.8 mL multi-dose vial kit for hormonal therapy, with channel expansion into mail order and retail pharmacy.

24Dehydrated Alcohol Injection, USP
CategorySterile Injectable / Therapeutic
Description

Generic equivalent of Ablysinol; 5 mL ≥99% ethyl alcohol single-dose vials for therapeutic neurolysis.

25Diphenhydramine Hydrochloride Injection, USP
CategorySterile Injectable / Antihistamine
Description

Generic equivalent of BENADRYL; 50 mg per mL single-dose vial antihistamine for treating allergic reactions, motion sickness, and parkinsonism.

26Tranexamic Acid in 0.7% Sodium Chloride Injection
CategorySterile Injectable / Ready-to-Use Premix
Description

Ready-to-use tranexamic acid in 0.7% sodium chloride, 1000 mg per 100 mL, for reducing or preventing hemorrhage in hemophilia patients during tooth extraction.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-05-01
Description

Milla Pharmaceuticals, the U.S. subsidiary of A.forall, partnered with Avenacy to manufacture and distribute Magnesium Sulfate in Water for Injection. Milla Pharmaceuticals is part of Avenacy's global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.

Strategic tierCoreTypeTechnology or Integration
Description

FDA-approved cGMP-certified contract manufacturing organization. Part of Avenacy's global network of development and manufacturing partners. Manufactured Melphalan Hydrochloride for Injection.

Strategic tierCoreTypeTechnology or Integration
Description

Listed as the Abbreviated New Drug Application (ANDA) holder for some products including Melphalan Hydrochloride. Part of Avenacy's development and manufacturing partner network.

4Global Development and Manufacturing Partner Network
Strategic tierCoreTypeTechnology or Integration
Description

Avenacy has nearly 20 development and manufacturing partners across five key geographies. These partners have undergone successful FDA inspections based on cGMP standards and form the foundation of the company's supply chain resiliency strategy.

avenacy.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Hospira (Pfizer CentreOne / Pfizer Injectables)
TypeBroad incumbent
Description

Hospira, now part of Pfizer, is the historical U.S. market leader in generic injectable pharmaceuticals. Its broad portfolio across essentially every therapeutic category Avenacy addresses makes it the principal broad incumbent competitor in U.S. hospital injectable supply.

TypeDirect peer
Description

Fresenius Kabi is one of the largest global manufacturers of generic sterile injectable pharmaceuticals, including products directly overlapping Avenacy's portfolio (e.g., Melphalan via the APP legacy). It is the same buyer (hospitals) via the same wholesale channels, making it a primary direct competitor.

3Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is one of the world's largest generics manufacturers with a meaningful sterile injectables portfolio and global manufacturing footprint. While not specialty-focused, it competes directly with Avenacy in many of the same generic injectable SKUs in U.S. hospitals.

TypeBroad incumbent
Description

B. Braun is a global medical products and injectable pharmaceutical company with strong U.S. hospital relationships, particularly in IV solutions and anesthesia-related injectables that overlap with Avenacy's Propofol and Lidocaine franchises. It is a relevant broad incumbent competitor.

TypeBroad incumbent
Description

Baxter is a large, diversified medical products manufacturer with a significant injectable and infusion pharmaceuticals portfolio competing for the same hospital purchasing decisions as Avenacy. Its broad portfolio and global scale make it a relevant broad incumbent comparable.

TypeDirect peer
Description

Sagent is a specialty injectable generics company also founded by Avenacy CEO Jeff Yordon, and is therefore the closest comparable in portfolio strategy, customer base (hospitals and alternate care), and commercial model. Avenacy explicitly mirrors Sagent's playbook, and Sagent's prior acquisition by Nichi-Iko provides a relevant valuation reference.

TypeDirect peer
Description

Amphastar is a U.S.-based specialty injectable generics company with a portfolio that overlaps substantially with Avenacy's (e.g., critical care injectables, propofol-adjacent products). It serves the same hospital and alternate care customers through similar wholesale channels, making it a strong direct comparable.

8Athenex Pharmaceutical Division
TypeDirect peer
Description

Athenex's pharmaceutical division, where CEO Jeff Yordon previously served as President, was a specialty injectable business launching 50+ products with strong U.S. hospital sales growth. It is a near-identical strategic template to Avenacy and a direct historical comparable.

TypeDirect peer
Description

Hikma is a leading global generic injectable manufacturer with a substantial U.S. hospital-focused sterile injectables franchise (including the former West-Ward and Bedford assets). It competes head-to-head with Avenacy in the same ANDA-based generic injectables sold through U.S. wholesalers to hospitals.

TypeBroad incumbent
Description

Teva is a global generics leader with a broad sterile injectables portfolio serving U.S. hospitals and clinics. Although much larger and broader than Avenacy, it is a relevant incumbent comparable for pricing, supply continuity, and formulary dynamics in the U.S. injectable generics market.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avenacy

Generic Injectable Pharmaceuticalsavenacy.com

Avenacy is a U.S. specialty pharmaceutical company founded in 2023 that commercializes FDA-approved generic sterile injectable medications across oncology, antibiotics, cardiovascular, and critical care through a network of cGMP manufacturing partners, selling to hospitals, clinics, and pharmacies via wholesale distribution and a growing field sales team.

What Avenacy does

Avenacy is a U.S. specialty pharmaceutical company founded in October 2023 and headquartered in Schaumburg, Illinois, focused on commercializing FDA-approved generic sterile injectable medications for acute care hospitals, outpatient clinics, physician offices, and — more recently — mail order and retail pharmacy channels. The company operates an asset-light model, sourcing its 28 launched products (as of June 2026) from a global network of nearly 20 cGMP-certified development and manufacturing partners across five key geographies. Its portfolio spans oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular and anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), a foundational antibiotic portfolio (Ampicillin, Penicillin G, Piperacillin-Tazobactam, Nafcillin, Doxycycline, Ampicillin-Sulbactam), anesthetics (Propofol, Lidocaine), and other critical care injectables (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine, Diphenhydramine, Bortezomib).

Avenacy differentiates through proprietary highly-visible label designs intended to reduce administration errors and improper doses, as well as ready-to-use formulations such as Magnesium Sulfate premix IV bags and Tranexamic Acid in 0.7% Sodium Chloride. Products are distributed primarily through U.S. wholesale distribution partners, with the company building a regional field sales team of Regional Business Development Managers to develop direct relationships with hospital and alternate care purchasers. Management is led by CEO and co-founder Jeff Yordon (formerly of Sagent Pharmaceuticals and Athenex Pharmaceutical Division), co-founder Kam Phulwani, and co-founder and board member Dr. Patrick Soon-Shiong (NantCapital).

The company generates revenue through unit sales of generic injectable pharmaceuticals at undisclosed pricing, with individual product U.S. market sizes ranging from approximately $8 million to $71 million annually. Avenacy has reported FY2025 year-over-year revenue growth of 212% and gross profit expansion of 335%, with over 3 million units sold since January 2024 and a 25-product milestone achieved by year-end 2025. It has raised capital through a NantCapital investment (August 2024), an approximately $26 million equity round (November 2024), and an Asset Based Lending facility with Texas Capital Bank (June 2025), supporting plans to launch 14 or more additional products in 2026 and continued channel expansion.

Avenacy firmographics

Firmographics
Name
Avenacy
Legal name
Avenacy, Inc.
Website
https://avenacy.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Avenacy is a U.S. specialty pharmaceutical company founded in 2023 that commercializes FDA-approved generic sterile injectable medications across oncology, antibiotics, cardiovascular, and critical care through a network of cGMP manufacturing partners, selling to hospitals, clinics, and pharmacies via wholesale distribution and a growing field sales team.
Ownership category
akta.pro rank

Avenacy industry classification

Industry
Product category
Generic Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAC
Sterile Injectable Generics

Keywords

  • Generic injectable pharmaceuticals
  • Sterile injectable medications
  • Specialty pharmaceutical manufacturing
  • Critical care injectables
  • Generic drug distribution

Where Avenacy is headquartered

Location

Headquarters

HQ city
Schaumburg
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avenacy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Generic Injectable Pharmaceuticals Sales: Avenacy generates revenue through the sale of FDA-approved generic injectable medications to healthcare facilities including hospitals, outpatient clinics, and physician offices. Products are distributed through wholesale partners. Each product launch represents a potential revenue stream from unit sales, with market sizes for individual products ranging from approximately $8 million to $71 million annually in the U.S.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Avenacy product offering

Product offering

Core offering

Avenacy is a specialty pharmaceutical company that develops, manufactures, and distributes FDA-approved generic injectable medications for U.S. healthcare facilities. Its portfolio of 28 launched sterile injectable products spans oncology, antibiotics, antiemetics, cardiovascular, and anesthesia therapeutic areas. Avenacy differentiates through proprietary highly visible packaging/labeling and ready-to-use formulations designed to reduce administration errors, leveraging a global network of nearly 20 cGMP-certified development and manufacturing partners.

Product overview

Avenacy is a specialty pharmaceutical company offering a portfolio of sterile injectable generic medications for U.S. healthcare facilities. The product portfolio consists of FDA-approved generic equivalents of branded injectable drugs spanning multiple therapeutic areas including oncology (Melphalan, Fulvestrant, Zoledronic Acid), cardiovascular/anticoagulation (Bivalirudin, Eptifibatide), antiemetics (Fosaprepitant, Palonosetron, Metoclopramide), antibiotics (Ampicillin, Penicillin G, Piperacillin/Tazobactam, Nafcillin, Doxycycline), anesthetics (Lidocaine, Propofol), and other critical care medications (Furosemide, Magnesium Sulfate, Tranexamic Acid, Dexmedetomidine). The portfolio includes both standard vials and ready-to-use formulations. The company differentiates through unique packaging and labeling designed to reduce medication errors. The products are distributed to acute care hospitals, outpatient clinics, and physician offices through wholesale partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Melphalan for Injection Generic equivalent of Alkeran; 50 mg lyophilized powder kit for palliative treatment of multiple myeloma, supplied to hospitals and oncology treatment centers.
  • Bivalirudin for Injection Generic equivalent of Angiomax; 250 mg lyophilized powder single-dose vial anticoagulant used during percutaneous coronary intervention (PCI) and for heparin-induced thrombocytopenia.
  • Fosaprepitant for Injection Generic equivalent of Emend; 150 mg single-dose vial antiemetic for chemotherapy-induced nausea and vomiting in oncology settings.
  • Fulvestrant Injection Generic equivalent of Faslodex; 250 mg per 5 mL prefilled syringe for HR-positive, HER2-negative advanced breast cancer.
  • Furosemide for Injection, USP Generic equivalent of Lasix; 100 mg per 10 mL loop diuretic for edema associated with congestive heart failure, cirrhosis, and renal disease.
  • Desmopressin Acetate for Injection, USP Generic equivalent of DDAVP; 4 mcg/mL single-dose and 40 mcg/10 mL multi-dose vials for central diabetes insipidus, hemophilia A, and von Willebrand's disease.
  • Eptifibatide Injection Generic equivalent of Integrilin; 75 mg per 100 mL antiplatelet for acute coronary syndrome and PCI procedures.
  • Magnesium Sulfate in Water for Injection Ready-to-Use Premix IV bags of magnesium sulfate in 2g/50mL, 4g/100mL, and 4g/50mL concentrations for seizure prevention in preeclampsia/eclampsia and other obstetric and critical care uses.
  • Isoproterenol Hydrochloride Injection, USP Generic equivalent of ISUPREL; 0.2 mg/mL and 1 mg/5 mL presentations for heart block, cardiac arrest, bronchospasm during anesthesia, and shock states.
  • Tranexamic Acid Injection, USP Generic equivalent of Cyklokapron; 1000 mg per 10 mL antifibrinolytic for reducing hemorrhage in hemophilia patients during tooth extraction and related bleeding indications.
  • Prochlorperazine Edisylate Injection, USP Generic equivalent of COMPAZINE; 10 mg per 2 mL multi-dose vial phenothiazine for controlling severe nausea/vomiting and schizophrenia.
  • Palonosetron Hydrochloride Injection, USP Generic equivalent of Aloxi; 5-HT3 antagonist antiemetic for chemotherapy-induced and postoperative nausea and vomiting.
  • Metoclopramide Injection, USP Generic equivalent of Reglan; 10 mg per 2 mL for diabetic gastroparesis, chemotherapy-induced nausea, postoperative nausea, small bowel intubation, and radiological examination.
  • Dexmedetomidine Injection, USP Generic equivalent of Precedex; 200 mcg per 2 mL single-dose vial sedative for ICU and procedural sedation.
  • Zoledronic Acid Injection Generic equivalent of Zometa; 4 mg per 5 mL single-dose vial bisphosphonate for bone metastases and hypercalcemia of malignancy.
  • Ampicillin for Injection, USP Ampicillin broad-spectrum penicillin antibiotic in 10 g pharmacy bulk package for treating susceptible bacterial infections in hospital settings.
  • Ampicillin and Sulbactam for Injection, USP Ampicillin-sulbactam combination antibiotic in 1.5 g, 3 g single-dose vials and 15 g pharmacy bulk package for treating bacterial infections.
  • Nafcillin for Injection, USP Nafcillin penicillinase-resistant penicillin antibiotic in 10 g pharmacy bulk package for treating staphylococcal infections.
  • Penicillin G Potassium for Injection, USP Penicillin G Potassium antibiotic in 5,000,000 and 20,000,000 unit glass vials for treating susceptible bacterial infections.
  • Piperacillin and Tazobactam for Injection, USP Piperacillin-tazobactam combination antibiotic in 3.375 g, 4.5 g single-dose vials and 40.5 g pharmacy bulk package for treating bacterial infections.
  • Propofol Injectable Emulsion, USP Generic equivalent of Diprivan; 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL single-dose vials for sedation and anesthesia.
  • Lidocaine HCl Injection, USP Generic equivalent of XYLOCAINE; 1% lidocaine in 20 mg/2 mL, 50 mg/5 mL, 300 mg/30 mL, and 500 mg/50 mL presentations for local or regional anesthesia.
  • Leuprolide Acetate Injection 14 mg per 2.8 mL multi-dose vial kit for hormonal therapy, with channel expansion into mail order and retail pharmacy.
  • Dehydrated Alcohol Injection, USP Generic equivalent of Ablysinol; 5 mL ≥99% ethyl alcohol single-dose vials for therapeutic neurolysis.
  • Diphenhydramine Hydrochloride Injection, USP Generic equivalent of BENADRYL; 50 mg per mL single-dose vial antihistamine for treating allergic reactions, motion sickness, and parkinsonism.
  • Tranexamic Acid in 0.7% Sodium Chloride Injection Ready-to-use tranexamic acid in 0.7% sodium chloride, 1000 mg per 100 mL, for reducing or preventing hemorrhage in hemophilia patients during tooth extraction.

Quantifiable outcome

  • Over 3 million units sold since January 2024
  • +2 more outcomes

Companies that use Avenacy

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Avenacy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Avenacy partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • Milla Pharmaceuticals Inc. (A.forall)majorTechnology or Integration · 1 May 2024Milla Pharmaceuticals, the U.S. subsidiary of A.forall, partnered with Avenacy to manufacture and distribute Magnesium Sulfate in Water for Injection. Milla Pharmaceuticals is part of Avenacy's global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
  • Qilu Pharmaceutical, Ltd.coreTechnology or IntegrationFDA-approved cGMP-certified contract manufacturing organization. Part of Avenacy's global network of development and manufacturing partners. Manufactured Melphalan Hydrochloride for Injection.
  • Arthur GroupcoreTechnology or IntegrationListed as the Abbreviated New Drug Application (ANDA) holder for some products including Melphalan Hydrochloride. Part of Avenacy's development and manufacturing partner network.
  • Global Development and Manufacturing Partner NetworkcoreTechnology or IntegrationAvenacy has nearly 20 development and manufacturing partners across five key geographies. These partners have undergone successful FDA inspections based on cGMP standards and form the foundation of the company's supply chain resiliency strategy.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Avenacy competitors and assessment

Company assessment

Broad incumbents

  • Hospira (Pfizer CentreOne / Pfizer Injectables): Hospira, now part of Pfizer, is the historical U.S. market leader in generic injectable pharmaceuticals. Its broad portfolio across essentially every therapeutic category Avenacy addresses makes it the principal broad incumbent competitor in U.S. hospital injectable supply.
  • Sandoz (Novartis): Sandoz is one of the world's largest generics manufacturers with a meaningful sterile injectables portfolio and global manufacturing footprint. While not specialty-focused, it competes directly with Avenacy in many of the same generic injectable SKUs in U.S. hospitals.
  • B. Braun Medical: B. Braun is a global medical products and injectable pharmaceutical company with strong U.S. hospital relationships, particularly in IV solutions and anesthesia-related injectables that overlap with Avenacy's Propofol and Lidocaine franchises. It is a relevant broad incumbent competitor.
  • Baxter International: Baxter is a large, diversified medical products manufacturer with a significant injectable and infusion pharmaceuticals portfolio competing for the same hospital purchasing decisions as Avenacy. Its broad portfolio and global scale make it a relevant broad incumbent comparable.
  • Teva Pharmaceutical Industries: Teva is a global generics leader with a broad sterile injectables portfolio serving U.S. hospitals and clinics. Although much larger and broader than Avenacy, it is a relevant incumbent comparable for pricing, supply continuity, and formulary dynamics in the U.S. injectable generics market.

Direct peers

  • Fresenius Kabi: Fresenius Kabi is one of the largest global manufacturers of generic sterile injectable pharmaceuticals, including products directly overlapping Avenacy's portfolio (e.g., Melphalan via the APP legacy). It is the same buyer (hospitals) via the same wholesale channels, making it a primary direct competitor.
  • Sagent Pharmaceuticals: Sagent is a specialty injectable generics company also founded by Avenacy CEO Jeff Yordon, and is therefore the closest comparable in portfolio strategy, customer base (hospitals and alternate care), and commercial model. Avenacy explicitly mirrors Sagent's playbook, and Sagent's prior acquisition by Nichi-Iko provides a relevant valuation reference.
  • Amphastar Pharmaceuticals: Amphastar is a U.S.-based specialty injectable generics company with a portfolio that overlaps substantially with Avenacy's (e.g., critical care injectables, propofol-adjacent products). It serves the same hospital and alternate care customers through similar wholesale channels, making it a strong direct comparable.
  • Athenex Pharmaceutical Division: Athenex's pharmaceutical division, where CEO Jeff Yordon previously served as President, was a specialty injectable business launching 50+ products with strong U.S. hospital sales growth. It is a near-identical strategic template to Avenacy and a direct historical comparable.
  • Hikma Pharmaceuticals: Hikma is a leading global generic injectable manufacturer with a substantial U.S. hospital-focused sterile injectables franchise (including the former West-Ward and Bedford assets). It competes head-to-head with Avenacy in the same ANDA-based generic injectables sold through U.S. wholesalers to hospitals.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Avenacy social profiles

Digital presence

Avenacy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avenacy leadership team

Management profile

Number of profiles

Profiles3 records

Avenacy funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avenacy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avenacy

What does Avenacy do?

Avenacy is a specialty pharmaceutical company that develops, manufactures, and distributes FDA-approved generic injectable medications for U.S. healthcare facilities. Its portfolio of 28 launched sterile injectable products spans oncology, antibiotics, antiemetics, cardiovascular, and anesthesia therapeutic areas. Avenacy differentiates through proprietary highly visible packaging/labeling and ready-to-use formulations designed to reduce administration errors, leveraging a global network of nearly 20 cGMP-certified development and manufacturing partners.

Is Avenacy a public or private company?

Avenacy is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avenacy founded?

Avenacy was founded in 2023. It employs 11 to 50 people.

Where is Avenacy based?

Avenacy is headquartered in Schaumburg, United States, in the North America region.

How does Avenacy make money?

One revenue line is on record: generic Injectable Pharmaceuticals Sales.

Who are Avenacy's main competitors?

Broad incumbents on record are Hospira (Pfizer CentreOne / Pfizer Injectables), Sandoz (Novartis), B. Braun Medical, Baxter International and Teva Pharmaceutical Industries. Direct peers are Fresenius Kabi, Sagent Pharmaceuticals, Amphastar Pharmaceuticals, Athenex Pharmaceutical Division and Hikma Pharmaceuticals.

Does Avenacy have an API?

No public API is recorded for Avenacy.

What industry is Avenacy in?

Avenacy's product category is Generic Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAC, Sterile Injectable Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAvenacy Announces Launch of Cyclophosphamide for Injection, USP in the U.S. MarketAvenacy launched Cyclophosphamide for Injection, USP in the U.S. as a generic equivalent for Cytoxan, approved by the FDA. The product is indicated for malignant diseases and pediatric nephrotic syndrome, with U.S. sales of about $133 million for the year ending June 2026. Shipping to wholesale partners begins this week.BioSpaceAvenacy Announces Launch of Norepinephrine Bitartrate Injection, USP in the U.S. MarketAvenacy launched Norepinephrine Bitartrate Injection, USP in the U.S. as a generic equivalent for Levophed, approved by the FDA. The product is indicated to raise blood pressure in adult patients with severe acute hypotension and had U.S. sales of about $20 million for the twelve months ending March 2026.Business Wire BlogAvenacy Announces Launch of Ready-to-Use Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S. MarketAvenacy launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the U.S., its 27th product since 2023. The product, indicated for hemophilia patients after tooth extraction, has U.S. sales of about $30.2 million, with ready-to-use presentations accounting for $15 million.openPR.comEmerging Sub-Segments Transforming the Alkylating Agents Market LandscapeThe alkylating agents market is projected to reach $6.9 billion by 2030, growing at a compound annual growth rate of 5.2%, driven by increased oncology demand, aging populations, and expanding cancer screening programs. In June 2024, Dr. Reddy's Laboratories partnered with Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for the US oncology market, while Avenacy Inc. launched Melphalan Hydrochloride in January 2024 as a generic equivalent to Alkeran for Injection.Business Wire BlogAvenacy Announces Launch of Diphenhydramine Hydrochloride Injection, USP in the U.S. MarketAvenacy announced the launch of its Diphenhydramine Hydrochloride Injection, USP in the U.S. market, a generic equivalent of BENADRYL® approved by the FDA for treating allergic reactions, motion sickness, and parkinsonism. The product marks the company's 26th offering and first launch of 2026, with U.S. sales of approximately $17.2 million for the twelve months ending December 2025. Avenacy will begin shipping the single-dose vials to wholesale partners this week.Business Wire BlogAvenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare ConferenceAvenacy, a specialty pharmaceutical company, announced it achieved its goal of launching 25 critical injectable products by year-end 2025 with over 3 million units sold since January 2024. The company expects FY2025 year-over-year revenue growth of 212% and gross profit expansion of 335%, driven by sales of nearly 2.4 million units. For 2026, Avenacy plans to launch 14 or more products, having signed 20 products targeted for the next two years representing a combined market opportunity of approximately $2.5 billion.PharmiWeb.comAvenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare ConferenceAvenacy, a U.S.-based specialty pharmaceutical company, announced it achieved its goal of launching 25 critical injectable products by year-end 2025, having sold over 3 million units since January 2024, with 11 new products launched in the U.S. market during 2025 alone. The company expects FY2025 year-over-year revenue growth of 212% and gross profit expansion of 335%, driven by full-year 2025 sales of nearly 2.4 million units, and entered into an Asset Based Lending agreement with Texas Capital Bank in June 2025 to fund portfolio expansion. For 2026, Avenacy plans to launch 14 or more additional products, having signed 20 products targeted for launch over the next two years representing a combined market opportunity of approximately $2.5 billion.BioSpaceAvenacy Provides Update on Business Progress and Announces 2026 Strategic Priorities Ahead of 44th Annual J.P. Morgan Healthcare ConferenceAvenacy, a specialty pharmaceutical company, achieved its goal of launching 25 products by year-end 2025 with over 3 million units sold since January 2024, having launched 11 new products in the U.S. market including an antibiotic portfolio. The company expects FY2025 YoY revenue growth of 212% and gross profit expansion of 335%, driven by full-year 2025 sales of nearly 2.4 million units. For 2026, Avenacy plans to launch 14+ products, having signed 20 products targeted for launch over the next two years representing a combined market opportunity of approximately $2.5 billion.BioSpaceAvenacy to Attend 2025 ASHP Midyear Clinical Meeting and ExhibitionAvenacy, a specialty pharmaceutical company focused on critical injectable medications, announced it will attend the 2025 ASHP Midyear Clinical Meeting in Las Vegas from December 7-10, 2025, to connect with existing and potential customers and showcase its progress. The company has launched 25 essential medications since its inception in 2023, including 10 new products since early 2025, and highlighted its Dehydrated Alcohol Injection offered in a unique 5-vial pack for cost-effective inventory management. Avenacy's product portfolio features unique packaging and labeling designed to reduce administration errors and improve patient care in medically supervised settings.